NewGenIvf announces pricing of $1.25M public offering of shares and pre-funded warrants
NewGenIvf Group Limited announced today the public offering of up to $1.25 million in gross proceeds. The offering consists of 17,857,143 ordinary shares or pre-funded warrants at a price of $0.07 per share. Each pre-funded warrant is priced at $0.06999, with an exercise price of just $0.00001 per warrant. The warrants can be exercised immediately and remain exercisable until fully exercised.
The company plans to utilize the net proceeds for investments in K25.ai, debt restructuring, working capital, and general corporate purposes. Aegis Capital Corp. is the sole placement agent for the offering. The SEC declared the registration statement effective on September 28, 2026, and the transaction is expected to close on or about Wednesday, pending customary conditions.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
